Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand

© 2019 Deerochanawong et al. Aim: Liraglutide, a once-daily subcutaneous glucagon-like peptide-1 (GLP-1) agonist, is approved for treatment of hyperglycemia in patients with type 2 diabetes mellitus (T2DM). For patients with established cardiovascular diseases, liraglutide has also been shown to red...

Full description

Saved in:
Bibliographic Details
Main Authors: Chaicharn Deerochanawong, Natapong Kosachunhanun, Arvind V. Gadekar, Pitthaporn Chotikanokrat, Unchalee Permsuwan
Format: Journal
Published: 2019
Subjects:
Economics, Econometrics and Finance
Medicine
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85071682129&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/66653
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University

Internet

https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85071682129&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/66653

Similar Items